STIEFEL
SpecialtySTIEFEL is a specialty pharmaceutical company focused on Dermatology, Immunology, Infectious Disease.
STIEFEL at a Glance
- Strong track record with 99% execution quality across 42 trials
- Leading 7 drug targets across portfolio
STIEFEL's Key Drugs
STIEFEL's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
STIEFEL's Recent FDA Approvals
New NDA/BLA approvals for STIEFEL over the last two years — novel drugs only, excluding generics and label supplements.
STIEFEL's Therapeutic Areas
STIEFEL's approved drugs and pipeline span 3 therapeutic areas, led by Dermatology and Immunology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
STIEFEL's Top Competitors
STIEFEL's closest competitors by therapeutic-area and drug-target overlap include Pfizer, BAUSCH AND LOMB INC, and PHARMACIA AND UPJOHN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
STIEFEL Pipeline Snapshot
STIEFEL has 37 active clinical programs from ClinicalTrials.gov — 12 Phase 3, 2 Phase 2 and 23 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Dermatology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 11/11 completed
- • Speed: 4 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1996-10-28
- Latest
- 2023-02-22
- Applications
- 5
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges